STOCK TITAN

[SCHEDULE 13D/A] Guardian Pharmacy Services, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Bindley Capital Partners I, LLC ("Bindley Capital") currently owns an aggregate of 1,939,817 shares of Class A common stock, par value $0.001 per share ("Class A common stock") and 18,300,526 shares of Class B common stock, par value $0.001 per share ("Class B common stock"), of Guardian Pharmacy Services, Inc. (the "Issuer"). Pursuant to the Issuer's Amended and Restated Certificate of Incorporation (the "Charter"), such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Bindley Capital, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2025 (the "10-Q")), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 8, 10 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Bindley, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7 and 9 in the table above represent 35,714 outstanding shares of Class A common stock directly owned by Mr. Salentine, Jr. The shares reported in Rows 8 and 10 represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Salentine, Jr., and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The shares reported in Row 11 represent the aggregate amount of shares of Class A common stock beneficially owned by the Reporting Person. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Pharmacy Investors, LLC ("Pharmacy Investors") currently owns an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Pharmacy Investors, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
John Ackerman has voting and investment power over an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock currently owned by Pharmacy Investors by virtue of his position as Manager of Pharmacy Investors, LLC. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Mr. Ackerman, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Cardinal Equity Fund, L.P. ("Cardinal") currently owns an aggregate of 149,794 shares of Class A common stock and 1,413,171 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 149,794 outstanding shares of Class A common stock beneficially owned by Cardinal, and 471,057 shares of Class A common stock that will be issued to Cardinal on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. Investment and voting decisions for the shares held by Cardinal require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson, Darrell E. Zink and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
Fred P. Burke currently owns an aggregate of 413,019 shares of Class A common stock and 3,896,477 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 413,019 outstanding shares of Class A common stock beneficially owned by Mr. Burke, and 1,298,826 shares of Class A common stock that will be issued to Mr. Burke on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
David K. Morris currently owns an aggregate of 204,110 shares of Class A common stock and 1,925,608 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 204,110 outstanding shares of Class A common stock beneficially owned by Mr. Morris, and 641,869 shares of Class A common stock that will be issued to Mr. Morris on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
G. Kendall Forbes currently owns an aggregate of 193,521 shares of Class A common stock and 1,825,710 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 193,521 outstanding shares of Class A common stock beneficially owned by Mr. Forbes, and 608,570 shares of Class A common stock that will be issued to Mr. Forbes on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.


SCHEDULE 13D


Bindley Capital Partners I, LLC
Signature:/s/ Thomas J. Salentine, Jr.
Name/Title:Member
Date:07/29/2025
William E. Bindley
Signature:/s/ William E. Bindley, individually
Name/Title:William E. Bindley, individually
Date:07/29/2025
Thomas J. Salentine, Jr.
Signature:/s/ Thomas J. Salentine, Jr., individually
Name/Title:Thomas J. Salentine, Jr., individually
Date:07/29/2025
Pharmacy Investors, LLC
Signature:/s/ John Ackerman
Name/Title:Managing Member
Date:07/29/2025
John Ackerman
Signature:/s/ John Ackerman, individually
Name/Title:John Ackerman, individually
Date:07/29/2025
Cardinal Equity Fund, L.P.
Signature:/s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner
Name/Title:Managing Member
Date:07/29/2025
Fred P. Burke
Signature:/s/ Fred P. Burke, individually
Name/Title:Fred P. Burke, individually
Date:07/29/2025
David K. Morris
Signature:/s/ David K. Morris, individually
Name/Title:David K. Morris, individually
Date:07/29/2025
G. Kendall Forbes
Signature:/s/ G. Kendall Forbes, individually
Name/Title:G. Kendall Forbes, individually
Date:07/29/2025
Guardian Pharmacy Services, Inc.

NYSE:GRDN

GRDN Rankings

GRDN Latest News

GRDN Latest SEC Filings

GRDN Stock Data

1.54B
18.85M
15.09%
83.31%
0.54%
Medical Care Facilities
Retail-drug Stores and Proprietary Stores
Link
United States
ATLANTA